Nirsevimab is efficient for shielding infants towards respiratory syncytial virus (RSV)-associated decrease respiratory tract illness (LRTD), in line with a examine revealed on-line July 22 in Pediatrics.
Amber Hsiao, Ph.D., M.P.H., from the Kaiser Permanente Vaccine Examine Heart in Oakland, California, and colleagues examined nirsevimab effectiveness towards polymerase chain response (PCR)-confirmed RSV LRTD and RSV-associated well being care utilization in the course of the 2023 to 2024 RSV season at Kaiser Permanente Northern California.
The examine included 31,900 infants, 49.1% of whom acquired nirsevimab. The researchers recognized 35 and 462 RSV LRTD episodes amongst nirsevimab-immunized infants and nonimmunized infants (6.10 and 58.51/1,000 person-years, respectively). Nirsevimab effectiveness was 87.2%, 98.0%, and 71.0% towards RSV LRTD, hospitalized RSV LRTD, and PCR-confirmed RSV, respectively.
Fewer encounters (adjusted means distinction, −0.86) and decrease odds of hospitalization (odds ratio, 0.11) have been seen for nirsevimab-immunized infants with RSV LRTD than nonimmunized infants.
“These findings help the Advisory Committee on Immunization Apply’s advice for eligible infants aged
Extra data:
Amber Hsiao et al, Effectiveness of Nirsevimab In opposition to RSV and RSV-Associated Occasions in Infants, Pediatrics (2025). DOI: 10.1542/peds.2024-069510
2025 HealthDay. All rights reserved.
Quotation:
Nirsevimab efficient for shielding infants from RSV decrease respiratory tract illness (2025, July 30)
retrieved 30 July 2025
from https://medicalxpress.com/information/2025-07-nirsevimab-effective-infants-rsv-respiratory.html
This doc is topic to copyright. Other than any honest dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is offered for data functions solely.
